Close Menu

NEW YORK – Having recently completed a $12 million Series A funding round, liquid biopsy spinout C2i Genomics plans to initiate several retrospective and prospective validation trials on its minimal residual disease (MRD) detection platform, MRDetect, with undisclosed clinical centers in the US and Europe over the next year.

The New York-based firm believes MRDetect could be used to help physicians evaluate MRD status in a patient following tumor resection.

Get the full story with
360Dx Premium

Only $95 for the
first 90 days*

360Dx Premium gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives

Never miss another important industry story.

Try 360Dx Premium now.

You may already have institutional access!

Check if I qualify.

Already a 360Dx or GenomeWeb Premium member?
Login Now.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.
Sponsored by
LGC SeraCare Life Sciences

This webinar brings together an expert panel of stakeholders in cancer diagnostics and clinical care who will discuss the promise and challenges of liquid biopsy technologies in cancer diagnosis, monitoring, and patient care management.